Health & Fitness

According to FutureWise analysis the market for heart failure poc and loc devices in 2025 is US$ 0.11 billion, and is expected to reach US$ 0.34 billion by 2033 at a CAGR of 15.56%. Heart failure POC (Point-of-Care) and LOC (Lab-on-Chip) devices are increasingly important for providing rapid, near-patient diagnostics that facilitate quicker clinical decisions. The focus on early detection and remote monitoring is driving their use in hospitals, ambulatory centers, and home care. Advances in microfluidics and biomarker testing are improving accuracy, portability, and integration with digital health platforms. Heart failure, also referred to as congestive heart failure, occurs when the heart muscle is unable to pump blood effectively. This condition can lead to blood backing up and fluid accumulation in the lungs, causing symptoms such as shortness of breath. Various cardiac disorders, like coronary artery disease and high blood pressure, can gradually weaken or stiffen the heart, ... Continue reading →

According to FutureWise analysis, the market for heart pump device in 2025 is US$ 3.28 billion and is expected to reach US$ 9.76 billion by 2033 at a CAGR of 14.6%. The market is growing due to the rise in advanced-stage heart failure, the adoption of ventricular assist devices (VADs), and advancements in minimally invasive implantation techniques. Continuous-flow technologies and improved device durability are enhancing clinical adoption and patient outcomes. Heart pump devices, commonly known as mechanical circulatory support (MCS) systems, are essential tools in contemporary cardiology for patients with heart failure. These devices either support or completely take over the pumping function of the heart, which is crucial as cardiovascular diseases, particularly heart failure, continue to rise on a global scale. For patients who do not respond to traditional medical therapies, heart pump devices serve as life-saving solutions, ensuring adequate blood flow throughout the body and ... Continue reading →

According to FutureWise analysis the market for heart transplant in 2025 is US$ 11.92 billion, and is expected to reach US$ 25.10 billion by 2033 at a CAGR of 9.76%. The demand for heart transplantation is increasing due to the rise in end-stage heart failure and limited effectiveness of long-term medications. Improvements in organ preservation, better immunosuppressive drugs, and donor heart optimization technologies are boosting transplant success rates. Additionally, expanding global transplant programs and improved patient survival rates are further driving market growth. Heart transplantation is a medical procedure that involves replacing a damaged or diseased heart with a healthy one, allowing the recipient's heart to function normally. This option is generally considered for patients who are at high risk of developing end-stage heart disease or for those who have exhausted all other treatment options. A healthy heart can be preserved for up to six hours if kept frozen ... Continue reading →

According to FutureWise analysis the market for in 2025 is US$ 84.11 billion, and is expected to reach US$ 205.89 billion by 2033 at a CAGR of 11.84%. The increasing global prevalence of chronic hepatitis C infections, along with improved screening and diagnostic rates, is driving the demand for advanced therapies. Expanding access to highly effective direct-acting antivirals (DAAs) is improving treatment outcomes by providing shorter, safer, and more effective regimens. Hepatitis C treatment has undergone a substantial transformation in recent years, shifting from lengthy and often difficult therapies to highly effective and well-tolerated treatment options that can frequently lead to a cure. Hepatitis C is a viral infection that primarily affects the liver, causing inflammation, fibrosis, cirrhosis, and potentially leading to liver cancer or liver failure. Historically, treatment options were limited and success rates were modest, presenting challenges for patients who dealt with ... Continue reading →

According to FutureWise analysis the market for hepatocellular carcinoma (hcc) treatment in 2025 is US$ 4.30 billion, and is expected to reach US$ 17.51 billion by 2033 at a CAGR of 19.20%. The market expansion is fueled by the rising global prevalence of chronic liver diseases and the adoption of advanced therapies. Breakthrough combination treatments, better diagnostics, and expanding clinical trials are improving survival for HCC patients. Increased investments in precision oncology and biomarker-driven strategies are expected to drive further innovation and accessibility through 2033. Hepatocellular Carcinoma (HCC) is the predominant type of primary liver cancer and represents a significant global health challenge, largely driven by chronic liver conditions such as hepatitis B and C, prolonged alcohol consumption, non-alcoholic fatty liver disease (NAFLD), and various metabolic disorders. The development of HCC often occurs quietly over years of liver inflammation and fibrosis, ... Continue reading →

According to FutureWise analysis the market for HERG screening in 2025 is US$ 2.12 billion, and is expected to reach US$ 5.76 billion by 2033 at a CAGR of 13.31%. The increasing focus on cardiac safety assessment in drug development is a significant factor driving the adoption of hERG screening technologies. Pharmaceutical and biotech companies are progressively incorporating advanced in vitro and in silico assays to identify potential cardiotoxicity risks early in the development process. The human Ether-a-go-go-Related Gene (HERG) encodes for the Kv11.1 protein, a vital alpha subunit of a potassium ion channel. These channels play an essential role in regulating the heartbeat by facilitating a repolarizing current during the cardiac action potential. HERG assessments are crucial requirements set by regulatory agencies prior to the submission of Investigational New Drug applications. Various assays are employed for HERG screening, including manual or automated patch clamp assays, ... Continue reading →

According to FutureWise analysis the market for hernia mesh devices in 2025 is US$ 5.14 billion, and is expected to reach US$ 7.83 billion by 2033 at a CAGR of 5.40%. The demand for hernia mesh devices is rising due to more abdominal wall hernias, increased use of minimally invasive surgery, and advancements in materials like biologic and absorbable polymers. Modern mesh technologies improve patient outcomes by lowering recurrence rates and aiding recovery. Innovations in lightweight, composite, and 3D-mesh designs are expected to boost market adoption in the coming years. A hernia occurs when an organ or fatty tissue protrudes through a weak area in the surrounding muscle or connective tissue, known as fascia. This condition can arise when an organ or fatty tissue squeezes through a defect in the muscle or tissue that normally holds it in place. The most prevalent type of hernia is abdominal, though hernias can also affect regions such as the upper thigh, abdominal wall (often ... Continue reading →

According to FutureWise analysis, the heart valve devices market in 2025 is US$11.27 billion, and is expected to reach US$28.04 billion by 2033 at a CAGR of 12.07%.  The global heart valve devices market is on an exhilarating upward trajectory, driven by an increasingly aging population and the alarming rise of cardiovascular diseases around the world. One of the most thrilling developments in this domain is the surging popularity of transcatheter aortic valve replacement (TAVR) procedures. These innovative, minimally invasive alternatives to traditional open-heart surgery are revolutionizing patient care and are a pivotal force behind the market’s expansion. Currently, North America is leading the charge, benefiting from its advanced healthcare infrastructure and a strong appetite for embracing cutting-edge valve technologies. However, don’t overlook the Asia-Pacific region! It’s rapidly emerging as the fastest-growing segment of the market, bursting with ... Continue reading →

According to FutureWise analysis, the heart valves market in 2025 is US$12.34 billion, and is expected to reach US$29.20 billion by 2033 at a CAGR of 11.37%. The global heart valves market is experiencing an exhilarating surge, and the reasons behind this growth are impressive! With the rising prevalence of valvular heart diseases such as aortic stenosis and mitral regurgitation, particularly among the aging population, the demand for effective treatments is greater than ever. Innovative advancements in tissue-engineered valves and advanced polymer materials are not just improving valve durability — they’re significantly enhancing biocompatibility and reducing the need for repeat surgeries. But that's not all; the trend towards minimally invasive procedures is truly transforming the landscape of heart valve therapy. Transcatheter valve implantation techniques are rapidly gaining popularity, especially among high-risk patients seeking safer, less invasive ... Continue reading →

According to FutureWise analysis, the Hemagglutinin 5 Market in 2025 is US$1.58 billion, and is expected to reach US$2.67 billion by 2033 at a CAGR of 6.78%. A hemagglutinin is a naturally occurring glycoprotein that causes red blood cells (erythrocytes) to clump together, and these substances are present in plants, invertebrates, and certain microorganisms. The most well-characterized hemagglutinins serve as surface antigens—foreign proteins that trigger the production of antibodies—on viruses belonging to the Orthomyxoviridae family, which includes the influenza viruses, and the Paramyxoviridae family, known for a variety of pathogenic viruses such as measles. Notably, a highly pathogenic strain of the H5N1 avian flu has been found to infect humans at low rates. Research has identified single amino acid changes in the type H5 hemagglutinin of this avian virus strain in human patients, indicating that these alterations can significantly modify the receptor ... Continue reading →